Scientists identify new form of dementia
May 1, 2019Research and Development AD, Alzheimer's, dementia, late, neuroscience
A team of scientists from Britain and the United States have described a new form of dementia, according to a …
GSK’s Benlysta becomes first FDA-approved IV therapy for paediatric lupus
April 30, 2019Manufacturing and Production, Sales and Marketing Benlysta, FDA, GSK, Lupus, US, pharma
GSK has scored approval in the US with Benlysta (belimumab) for the treatment of systemic lupus erythematosus (SLE) in paediatric …
Two thirds of MPs believe NHS should spend less on medicines
April 30, 2019Manufacturing and Production Long Term Plan, MPs, NHS, UK, government, health, public health
Nearly two thirds (64%) of MPs believe the NHS should direct more resources towards prevention, over funding for new treatments, …
Donald Trump says he will not accept campaign money from pharma
April 30, 2019Manufacturing and Production Donald Trump, USA, campaign contributionss, pharma, politics
President Donald Trump has said he will not accept money from pharmaceutical companies in the run up to the 2020 …
New Phase 3 data confirms safety and efficacy of UCB’s Cimzia in plaque and psoriatic arthritis
April 30, 2019Manufacturing and Production, Research and Development Cimzia, UCB Pharma, pharma, plaque psoriasis, psoriasis
New Phase 3 data has been released by UCB Pharma on the safety of Cimzia (certolizumab pegol) in the treatment …
Stanford scientists develop test for ME
April 30, 2019Manufacturing and Production CFS, ME, diagnosis, electric curernt, immune system, nanoelectronic assay
Scientists from Stanford University have, for the first time, developed a test for Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The blood …
The price of access: Can the NHS afford Orkambi?
April 29, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Drug pricing, NHS, NICE, Orkambi, UK, Vertex, access, cystic fibrosis, feature, pharma, pricing
The impasse over access to Vertex’s Orkambi for cystic fibrosis patients in England and Wales has revealed the cracks in …
Sanofi and Lexicon’s Zynquista scores EU approval for type 1 diabetes patients
April 29, 2019Sales and Marketing Lexicon, Sanofi, Type 1 diabetes, Zynquista, diabetes, pharma
The European Commission has authorised the use of Sanofi and Lexicon’s Zynquista (sotagliflozin) in Europe in the treatment of specific …
Gilead subsidiary Kite Pharma to open CAR-T manufacturing facility in Maryland
April 29, 2019Manufacturing and Production, Sales and Marketing CAR-T, Gilead, Manufacturing Facility, Maryland, kite pharma
Gilead Sciences subsidiary Kite Pharma has announced plans to open a new CAR-T manufacturing facility in Frederick County, Maryland (US). …
AZ and MSD’s Lynparza secures CHMP nod in first-line BRCA-mutated ovarian cancer
April 29, 2019Sales and Marketing AstraZeneca, CHMP, Cancer, MSD, lynparza, ovarian cancer, pharma
AstraZeneca and MSD’s Lynparza (olaparib) has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use …
India hits back at claims they are leading source of counterfeit drugs
April 29, 2019Sales and Marketing
India has rejected claims that they, along with China, are the chief source of counterfeit medicines around the world. In …
Opioids to be labelled with addiction warning in UK
April 29, 2019Sales and Marketing
All opioid medicines sold in the UK will be labelled with a warning as to the potential for addiction, Health …
Gilead’s selonsertib crashes at Phase 3 in NASH
April 26, 2019Medical Communications, Research and Development, Sales and Marketing Gilead, nash, pharma, selonsertib
Gilead has broken the news that its apoptosis signal-regulating kinase 1 (ASK1) inhibitor selonsertib failed to meet its primary endpoint …
Top Ten most popular articles on Pharmafile.com this week!
April 26, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Aduro Biotech, Cancer, GSK, ICR, J&J, JJ, Novartis, Sandoz, pharma
The Institute for Cancer Research (ICR) called for new measures to increase the speed with which patients in the UK …
Senior GSK exec Richard Saynor revealed as new Sandoz CEO
April 26, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Novartis has seen a major leadership change within its business, as the company announced that senior GlaxoSmithKline exec Richard Saynor …
Eli Lilly to withdraw Lartruvo from market in soft tissue sarcoma following Phase 3 failure
April 26, 2019Medical Communications, Sales and Marketing Cancer, Eli Lilly, Lartruvo, pharma, soft tissue sarcoma
Eli Lilly has revealed it is to withdraw its platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody Lartruvo (olaratumab) from …
Funding to fight malaria falls $2 billion short of WHO target, study shows
April 26, 2019Medical Communications WHO, developing countires, funding, health economics, infectious diseases, malaria
Global spending on the fight against malaria has stalled, falling $2 billion short of World Health Organization (WHO) targets, according …
Researchers find Achilles’ heel protein in leukaemia
April 26, 2019Medical Communications AML, Edinburgh, Protein, YTHDF2, blood cancer, drug targets, leukaemia
An international team of researchers have identified an “Achilles’ heel” protein that could lead to the development of novel treatments …
FDA approves Beximco’s generic version of MSD’s allergy drug Periactin
April 25, 2019Sales and Marketing FDA, MSD, Periactin, allergy, generics, pharma
Bangladesh-based Beximco Pharma is celebrating following the decision from the FDA to approve its generic version of MSD’s antihistamine therapy …
Pharmacists should review care homes residents’ medicine regimens to reduce polypharmacy
April 25, 2019Medical Communications care homes, older people, pharmacists, pharmacy, polypharmacy
Pharmacists should review older people’s medicines regimens in order to reduce inappropriate polypharmacy, according to the Royal Pharmaceutical Society (RPS). …
Latest content
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
